Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06772870
PHASE1

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

Sponsor: Design Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.

Official title: A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2025-02

Completion Date

2025-12

Last Updated

2025-02-21

Healthy Volunteers

Yes

Interventions

DRUG

DT-216P2

DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.

DRUG

Saline

Normal saline solution will be used as placebo control.

Locations (1)

Nucleus Network, Level 5, 89 Commercial Road

Melbourne, Victoria, Australia